AdvaMed Names New Head of Orthopedics Sector
By Advanced Medical Technology Association | January 24, 2017
The Advanced Medical Technology Association (AdvaMed) has announced that Juan-José Gonzalez, president, U.S. DePuy Synthes, part of the Johnson & Johnson Family of Companies, has been named head of the organization’s Orthopedics Sector. In this role, Gonzalez will help lead and coordinate the regulatory and reimbursement ad-vocacy priorities that particularly impact AdvaMed’s orthopedic member companies.
As head of U.S. DePuy Synthes, Gonzalez leads a more than $5 billion orthopedic business and is responsible for all strategic and commercial activities. In his decade at Johnson & Johnson, he has held a number of management roles of increasing responsibility, most recently serving as president, DePuy Synthes Europe, Middle East and Africa (EMEA), where he led the team driving innovation and growth across the EMEA region by leveraging a broad port-folio to address customer needs in the changing market environment. Gonzalez also has a passion and successful track record for driving talent development within his organization and serves as an ongoing mentor to many within Johnson & Johnson.
“With his breadth of experience and knowledge of global markets, Juan-José is an excellent choice to lead AdvaMed’s Orthopedics Sector and to advocate worldwide for patient access to needed mobility technologies,” said AdvaMed senior vice president Tara Federici, staff lead for the sector.
Priority issues for the association’s Orthopedic Sector include:
- Working with key stakeholders on the design, devel-opment and maintenance of an effective orthopedic device registry in the U.S.; and
- Ensuring the value of orthopedic implants is captured in new payment methodologies.
– See more at: http://www.odtmag.com/contents/view_breaking-news/2017-01-24/advamed-names-new-head-of-orthopedics-sector#sthash.ek3eb20Q.dpuf
OrthoSpineNews
OrthoSpineNews.com is the preferred aggregator of all news in the orthopedic and spine industry. You can subscribe for our daily email, follow us on twitter or download our app for iPhone and Android.